eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
10/2003
vol. 7
 
Share:
Share:
more
 
 
abstract:

Clinical course of breast cancer in carriers of BRCA1 germline mutations

Beata Utracka-Hutka
,
Dariusz Lange
,
Elżbieta Nowicka
,
Ewa Grzybowska
,
Helena Zientek
,
Jadwiga Rogozińska-Szczepka
,
Katarzyna Behrendt
,
Rafał Suwiński

Współcz Onkol (2003) vol. 7, 10 (742-753)
Online publish date: 2003/12/17
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose: To compare clinical prognosis of breast cancer in three different groups of patients: 46 BRCA1 mutation carriers (BRCA1+), 46 BRCA1 mutation non-carriers (BRCA1-), and 48 patients, who never had genetic counselling (CG).
Material and methods: Patients were treated for breast cancer in the Center of Oncology in Gliwice between 1972 and 2002. Local recurrence rate (RFS), metastases free survival (MFS), incidence of second cancer, disease-free survival (DFS) and overall survival (OS) were analysed using Cox model. Results: The actuarial 10-year RFS was 95% in BRCA1+ group and was significantly higher than in BRCA1- and CG groups (71% and 50%, respectively). The corresponding 10-year metastases-free survival in BRCA1+, BRCA1- and CG groups was 82%, 67% and 49% respectively. A remarkably high incidence of second breast cancer in BRCA1+ and BRCA1- groups (46% and 50%) compared to 2% in the control group can be attributed to counseling criteria. 10 patients from BRCA1+ group developed ovarian cancer compared to only 1 in BRCA1- group and 0 in CG group. The actuarial 10-year overall survival was significantly higher in BRCA1+ and BRCA1- groups (78.5% and 80%, respectively) as compared to the control group (32%).
Conclusions: The overall survival of BRCA1 mutation carriers did not differ significantly from non-carriers due to frequent occurrence of hereditary ovarian cancers that eventually remained loco-regionally uncontrolled. Patients with sporadic breast cancer presented in the most advanced stages, and carried the most unfavorable prognosis. This shows that the counseling itself may carry the bias of artificially increasing survival times by excluding patients with the most advanced disease at the diagnosis.
keywords:

mutated BRCA1 gene, breast cancer, prognostic factors, predictive factors

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe